广生堂: 关于股票交易异常波动的公告

Core Viewpoint - The stock of Fujian Guangshentang Pharmaceutical Co., Ltd. has experienced significant price fluctuations, with a cumulative increase of over 30% from July 29 to July 31, 2025, despite no major changes in the company's fundamentals [1][2]. Group 1: Stock Trading Anomalies - The company's stock price has shown abnormal volatility, with a cumulative closing price deviation exceeding 30% over three consecutive trading days [2][3]. - The latest price-to-book ratio for the company is 46.58, significantly higher than the industry average of 3.17 for the pharmaceutical manufacturing sector [1]. Group 2: Clinical Trial Updates - The company has successfully enrolled the first subject in the Phase III clinical trial for its innovative hepatitis B treatment, GST-HG141, at the Shulan (Hangzhou) Hospital [2][3]. - The successful enrollment does not guarantee market approval, and the short-term impact on the company's performance is expected to be minimal [2][4]. Group 3: Financial Performance - The net profits attributable to shareholders for the company were reported as -127.40 million, -348.59 million, -156.30 million, and -28.49 million [1][3].